Half-year report · Q2

Period2024-01-01 → 2024-06-30
Filed2024-08-08
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥316m2024-01-01 → 2024-06-30Cons.Net sales
Revenue¥1.6bn2023-01-01 → 2023-12-31Cons.Net sales (5-year summary)
Revenue¥501m2023-01-01 → 2023-06-30Cons.Net sales
Operating income−¥1.1bn2024-01-01 → 2024-06-30Cons.Operating income
Operating income−¥864m2023-01-01 → 2023-06-30Cons.Operating income
Ordinary income−¥1.1bn2024-01-01 → 2024-06-30Cons.Ordinary income
Ordinary income−¥1.1bn2023-01-01 → 2023-12-31Cons.Ordinary income loss (5-year summary)
Ordinary income−¥868m2023-01-01 → 2023-06-30Cons.Ordinary income
Profit before tax−¥1.1bn2024-01-01 → 2024-06-30Cons.Income before income taxes
Profit before tax−¥869m2023-01-01 → 2023-06-30Cons.Income before income taxes
Net income (owners)−¥1.1bn2024-01-01 → 2024-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)−¥1.2bn2023-01-01 → 2023-12-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥886m2023-01-01 → 2023-06-30Cons.Profit loss attributable to owners of parent
Net income−¥1.1bn2024-01-01 → 2024-06-30Cons.Profit loss
Net income−¥886m2023-01-01 → 2023-06-30Cons.Profit loss
Total assets¥3.7bnat 2024-06-30Cons.Assets
Total assets¥4.3bnat 2023-12-31Cons.Assets
Total assets¥4.6bnat 2023-06-30Cons.Total assets (5-year summary)
Total liabilities¥470mat 2024-06-30Cons.Liabilities
Total liabilities¥472mat 2023-12-31Cons.Liabilities
Net assets / equity¥3.2bnat 2024-06-30Cons.Net assets
Net assets / equity¥3.9bnat 2023-12-31Cons.Net assets
Net assets / equity¥4.1bnat 2023-06-30Cons.Net assets (5-year summary)
Cash and deposits¥3.0bnat 2024-06-30Cons.Cash and deposits
Cash and deposits¥2.9bnat 2023-12-31Cons.Cash and deposits
Cash & equivalents¥3.0bnat 2024-06-30Cons.Cash and cash equivalents
Cash & equivalents¥2.9bnat 2023-12-31Cons.Cash and cash equivalents
Cash & equivalents¥3.7bnat 2023-06-30Cons.Cash and cash equivalents
Cash & equivalents¥3.4bnat 2022-12-31dCons.Cash and cash equivalents
Operating cash flow−¥222m2024-01-01 → 2024-06-30Cons.Net cash provided by used in operating activities
Operating cash flow−¥1.7bn2023-01-01 → 2023-12-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow−¥939m2023-01-01 → 2023-06-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥7m2024-01-01 → 2024-06-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥11m2023-01-01 → 2023-12-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥7m2023-01-01 → 2023-06-30Cons.Net cash provided by used in investment activities
Financing cash flow¥279m2024-01-01 → 2024-06-30Cons.Net cash provided by used in financing activities
Financing cash flow¥1.2bn2023-01-01 → 2023-12-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥1.2bn2023-01-01 → 2023-06-30Cons.Net cash provided by used in financing activities
EPS (basic)¥-63.252024-01-01 → 2024-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-68.622023-01-01 → 2023-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-53.812023-01-01 → 2023-06-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio87.2%at 2024-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio89.1%at 2023-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio89.9%at 2023-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 8
SegmentItemPeriodValue
jpcrp040300-q2r_E00987-000Drug Discovery Businessreportable segmentsegment profit2024-01-01 → 2024-06-30−¥1.1bn
jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segmentrevenue2024-01-01 → 2024-06-30¥316m
jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segmentrevenue external2024-01-01 → 2024-06-30¥316m
jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segmentsegment profit2024-01-01 → 2024-06-30−¥24m
jpcrp040300-q2r_E00987-000Drug Discovery Businessreportable segmentsegment profit2023-01-01 → 2023-06-30−¥1.0bn
jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segmentrevenue2023-01-01 → 2023-06-30¥501m
jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segmentrevenue external2023-01-01 → 2023-06-30¥501m
jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segmentsegment profit2023-01-01 → 2023-06-30¥169m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 417
ItemContextValueUnit
Current assetsPrior1YearInstant4191484000JPY
Current assetsCurrentQuarterInstant3544519000JPY
Property plant and equipmentPrior1YearInstant105498000JPY
Property plant and equipmentCurrentQuarterInstant99070000JPY
Intangible assetsPrior1YearInstant1091000JPY
Intangible assetsCurrentQuarterInstant679000JPY
Investments and other assetsPrior1YearInstant51817000JPY
Investments and other assetsCurrentQuarterInstant41380000JPY
Noncurrent assetsPrior1YearInstant158407000JPY
Noncurrent assetsCurrentQuarterInstant141130000JPY
AssetsPrior1YearInstant4349891000JPY
AssetsCurrentQuarterInstant3685650000JPY
Accounts payable tradePrior1YearInstant1200000JPY
Accounts payable tradeCurrentQuarterInstant-JPY
Current portion of long term loans payablePrior1YearInstant120000000JPY
Current portion of long term loans payableCurrentQuarterInstant70002000JPY
Accounts payable otherPrior1YearInstant190098000JPY
Accounts payable otherCurrentQuarterInstant257663000JPY
Income taxes payablePrior1YearInstant28273000JPY
Income taxes payableCurrentQuarterInstant23644000JPY
Other clPrior1YearInstant36349000JPY
Other clCurrentQuarterInstant19334000JPY
Current liabilitiesPrior1YearInstant375921000JPY
Current liabilitiesCurrentQuarterInstant370644000JPY
Long term loans payablePrior1YearInstant28402000JPY
Long term loans payableCurrentQuarterInstant18406000JPY
Asset retirement obligations nclPrior1YearInstant38657000JPY
Asset retirement obligations nclCurrentQuarterInstant38972000JPY
Other nclPrior1YearInstant29375000JPY
Other nclCurrentQuarterInstant42310000JPY
Noncurrent liabilitiesPrior1YearInstant96435000JPY
Noncurrent liabilitiesCurrentQuarterInstant99689000JPY
LiabilitiesPrior1YearInstant472356000JPY
LiabilitiesCurrentQuarterInstant470333000JPY
Capital stockPrior1YearInstant2076474000JPY
Capital stockCurrentQuarterInstant2258599000JPY
Capital surplusPrior1YearInstant5827683000JPY
Capital surplusCurrentQuarterInstant6009808000JPY
Retained earningsPrior1YearInstant-4075386000JPY
Retained earningsCurrentQuarterInstant-5169504000JPY
Treasury stockPrior1YearInstant-222000JPY
Treasury stockCurrentQuarterInstant-222000JPY
Shareholders equityPrior1YearInstant3828549000JPY
Shareholders equityCurrentQuarterInstant3098680000JPY
Valuation difference on available for sale securitiesPrior1YearInstant-2722000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant-3148000JPY
Deferred gains or losses on hedgesPrior1YearInstant-JPY
Deferred gains or losses on hedgesCurrentQuarterInstant27374000JPY
Foreign currency translation adjustmentPrior1YearInstant51709000JPY
Foreign currency translation adjustmentCurrentQuarterInstant92408000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2023-12-31pass
balance sheet identityconsolidated 2024-06-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-12-31pass
statement vs summary · net assetsconsolidated 2024-06-30pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-06-30pass
statement vs summary · net income attributable to parentconsolidated 2024-01-01/2024-06-30pass
statement vs summary · operating cash flowconsolidated 2023-01-01/2023-06-30pass
statement vs summary · operating cash flowconsolidated 2024-01-01/2024-06-30pass
statement vs summary · revenueconsolidated 2023-01-01/2023-06-30pass
statement vs summary · revenueconsolidated 2024-01-01/2024-06-30pass
statement vs summary · total assetsconsolidated 2023-12-31pass
statement vs summary · total assetsconsolidated 2024-06-30pass